Urothelial Carcinoma: Towards Integrated Biomarker Assessment
Trillium Pathology · 28.05.2026 · 4 (1) · 13
DOI: 10.47184/tp.2026.01.02 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trillium Pathology, online erschienen am 28.05.2026. Verfasst von Christopher Poremba und 1 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Advances in molecular diagnostics have reshaped the understanding of urothelial carcinoma beyond conventional stage-based classification. Genomic alterations, immune-related biomarkers and molecular subtypes provide complementary insights into tumour biology and therapeutic response. Integrating these parameters into routine diagnostics supports more precise treatment selection and reflects a shift towards multi-dimensional, biomarker-driven oncology.
Zitieren
APA
Poremba, C., & Siegert, S. I. (2026). Urothelial Carcinoma: Towards Integrated Biomarker Assessment. Trillium Pathology, 4(1), 13. https://doi.org/10.47184/tp.2026.01.02
Vancouver
Poremba C, Siegert SI. Urothelial Carcinoma: Towards Integrated Biomarker Assessment. Trillium Pathology. 2026;4(1):13. doi:10.47184/tp.2026.01.02
BibTeX
@article{Poremba2026,
author = {Poremba, Christopher and Siegert, Sabine Isabel},
title = {Urothelial Carcinoma: Towards Integrated Biomarker Assessment},
journal = {Trillium Pathology},
year = {2026},
volume = {4},
number = {1},
pages = {13},
doi = {10.47184/tp.2026.01.02}
}
EUVIMED